• Explore /
  • Poster
  • / <span>Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.</span>

Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.

Abstract Video & Slides Poster

Authors

Lorenzo Falchi

Lorenzo Falchi

Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY

Lorenzo Falchi , Michael Clausen , Fritz Offner , Sven de Vos , Joshua Brody , Kim M. Linton , Sylvia Snauwaert , Raul Cordoba , Jun Wu , Irina Bykhovski , Liwei Wang , Ali Rana , David Belada

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL

Clinical Trial Registration Number

NCT04663347

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7519)

DOI

10.1200/JCO.2023.41.16_suppl.7519

Abstract #

7519

Poster Bd #

70

Abstract Disclosures

Similar Posters

First Author: Laurie Helen Sehn

First Author: Lorenzo Falchi

First Author: Manfred Welslau

Poster

2023 ASCO Annual Meeting

Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.

Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.

First Author: Carrie Ho